Register Login
Register to leave comments
  • News bot Oct. 2, 2025, 5:26 p.m.

    📋 Aclaris Therapeutics, Inc. (ACRS) - Financial Results

    Filing Date: 2022-08-03

    Accepted: 2022-08-03 07:15:39

    Event Type: Financial Results

    Event Details:

    Aclaris Therapeutics Inc (ACRS) Reports Q3 2022 Financial Results Aclaris Therapeutics Inc (ACRS) announced its financial results for the period ending Q3 2022. Key Financial Highlights:
    • Revenue: 302
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 255824

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2022 2021 Change ($) Change (%)
    Costs And Expenses Loss From Operations -18.01K -39.90K $21.89K +54.87%
    Costs And Expenses Total Other Income Expense -155.00 580.00 $-735.00 -126.72%
    Costs And Expenses Net Loss -18.16K -39.32K $21.16K +53.81%
    Costs And Expenses Net Loss Per Share -0.34 -0.62 $0.28 +45.16%
    Cash Equivalents Marketable Securities 255.82K 255.82K $0.00 +0.00%
    Net Loss -39.32K -39.32K $0.00 +0.00%
    Revenue 310.00 310.00 $0.00 +0.00%
    Loss from Operations -20.99K -20.99K $0.00 +0.00%
    Net Loss -20.53K -20.53K $0.00 +0.00%
    Cash and Marketable Securities 255.82K 255.82K $0.00 +0.00%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Aclaris Therapeutics Inc
    • CIK: 0001557746
    • Ticker Symbol: ACRS
    • Period End Date: 2022-08-03
    • Document Type: 8-K

Search

News categories